The UK cell therapy biotech will now advance its first candidate cell therapy to clinical trials for treatment of liver ...

The newly opened Biotech Center of Excellence will be dedicated to developing and producing biological drugs, housing the ...

During the show, Quotient Sciences CEO Thierry Van Nieuwenhove will share insights on how the company is adapting to new FDA ...

At CPHI Milan 2024, Ardena will showcase its latest advancements in drug development and manufacturing, including the launch ...

At this October’s CPHI event being held in Milan, dsm-firmenich, is inviting stakeholders across the pharmaceutical market to ...

The company will introduce its innovative siliconized moulded glass vials, positioning itself as the only global supplier ...

As CPHI Milan 2024 approaches, Symbiosis Pharmaceutical Services is gearing up to showcase major expansions and innovations ...

The company, a provider of drug containment and delivery solutions, will introduce its expanded Vertiva 10mL on-body delivery ...

Bristol Myers Squibb (BMS) acquired Karuna Therapeutics, the developer of KarXT, in a deal worth US $14.0 billion in equity ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger ...

Large reduction in COGS: By 2025, EnzeneX 2.0 expects to produce 40 kg/1000 L batches at $40/gram, redefining FCCM economics. Lower operational costs and higher productivity can lead to up to 50% ...

A head-to-head study has revealed that CSL and Arcturus Therapeutic’s self-amplifying mRNA vaccine can maintain a stronger immune response than a conventional mRNA vaccine for up to one year and at a ...